ReviewAnnals of medicine and surgery (2012)2025
Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Can DPP-4 Inhibitors Improve Glycemic Control and Preserve Beta-Cell Function in Type 1 Diabetes Mellitus? A Systematic Review.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral antihyperglycemic agents commonly prescribed for type 2 diabetes (T2DM). Due to the intricate relationship between glucose regulation and cardiovascular diseases (CVDs), DPP-4 inhibitors have attracted attention for their cardiovascular safety and efficacy. This bibliometric analysis aims to provide insights into the global research landscape on DPP-4 inhibitors and cardiovascular outcomes (CVOs). Methods: A bibliometric analysis was performed, using the Web of Science Core Collection. Data were analyzed using VOSviewer, CiteSpace, and Biblioshiny. Results: The United States led in publication output, followed by Japan and China. Harvard University and the University of Toronto were the leading institutions. The most influential journals were Cardiovascular Diabetology and Diabetes Obesity & Metabolism. Darren K. McGuire was the most prolific author followed by Rury R. Holman. The most commonly occurring keyword was heart failure. Cluster analysis revealed key thematic areas in the field, including "incretin-based therapy," "dipeptidyl peptidase-4 inhibition," and "cardiovascular safety." Emerging clusters, such as "atrial fibrillation," have gained attention in recent years, highlighting evolving areas of investigation. Conclusion: This study underscores the importance of CVOs in the research on DPP-4 inhibitors. The high frequency of keywords such as "heart failure," along with recent terms like "mortality" and "risk," highlights a strong focus on cardiovascular safety and complications in the literature. Our analysis reflected that most studies address these critical aspects of cardiovascular health, discussing the potential role of DPP-4 inhibitors in mitigating adverse outcomes, particularly in patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.